trending Market Intelligence /marketintelligence/en/news-insights/trending/k01TSvlFLNRBqb9ELT2v0w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Delcath Systems plans $9.5M placement of units

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

Delcath Systems plans $9.5M placement of units

Delcath Systems Inc. plans to raise about $9.5 million in a private placement of company units.

Each unit under the placement will be sold at $1,000 each and will include one preferred share initially convertible into 16,667 common shares — at an initial price of 6 cents per share — and a common-stock purchase warrant.

Each warrant entitles the holder to buy one common share at an initial exercise price of 6 cents for a period of five years from the date of an anticipated reverse stock split at Delcath.

The placement is expected to close on Aug. 19.

Roth Capital Partners is acting as the sole placement agent for the transaction.

New York-based Delcath Systems develops healthcare equipment for treating liver cancers. Its investigational products include melphalan hydrochloride for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver.